» Articles » PMID: 16286021

Lymphotoxin-beta Receptor Signaling is Required for the Homeostatic Control of HEV Differentiation and Function

Overview
Journal Immunity
Publisher Cell Press
Date 2005 Nov 16
PMID 16286021
Citations 136
Authors
Affiliations
Soon will be listed here.
Abstract

The lymphotoxin axis is important for the maintenance of several specialized lymphoid microenvironments in secondary lymphoid tissue. Lymphoid-tissue architecture is highly plastic and requires continual homeostatic signaling to maintain its basal functional state. The cellularity of lymph nodes in adult mice was reduced by systemic blockade of lymphotoxin-beta receptor (LTbeta R) signaling with a soluble decoy receptor both in resting and reactive settings. This reduction in cellularity resulted from greatly impaired lymphocyte entry into lymph nodes due to decreased levels of peripheral lymph node addressing (PNAd) and MAdCAM on high endothelial venules (HEV). LTbeta R signaling was required to maintain normal levels of RNA expression of MAdCAM, and also of PNAd by regulating the expression of key enzymes and scaffold proteins required for its assembly. Thus, the homeostatic maintenance of functional HEV status in adult mice relies largely on LTbeta R signaling.

Citing Articles

Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes.

Chen K, De Giovanni M, Xu Y, An J, Kirthivasan N, Lu E Cell. 2024; 188(4):1019-1035.e22.

PMID: 39708807 PMC: 11845304. DOI: 10.1016/j.cell.2024.11.031.


Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.

Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z Signal Transduct Target Ther. 2024; 9(1):225.

PMID: 39198425 PMC: 11358547. DOI: 10.1038/s41392-024-01947-5.


Tertiary lymphoid structures and their therapeutic implications in cancer.

Chen X, Wu P, Liu Z, Li T, Wu J, Zeng Z Cell Oncol (Dordr). 2024; 47(5):1579-1592.

PMID: 39133439 DOI: 10.1007/s13402-024-00975-1.


Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma.

Gross N, Zhang Z, Mitchell J, Charmsaz S, Hernandez A, Coyne E JCI Insight. 2024; 9(18).

PMID: 39106104 PMC: 11457845. DOI: 10.1172/jci.insight.179292.


Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.

Yang F, Lee G, Fan Y Angiogenesis. 2024; 27(3):333-349.

PMID: 38580870 PMC: 11303583. DOI: 10.1007/s10456-024-09913-z.